Pan-cancer Analysis of LncRNA XIST and Its Potential Mechanisms in Human Cancers

Overview

Journal Heliyon

Specialty Social Sciences

Date 2022 Oct 10

PMID 36212008

Authors

Wei Han

Chun-Tao Shi

Jun Ma

Hua Chen

Qi-Xiang Shao

Xiao-Jiao Gao

Ying Zhou

Jing-Feng Gu

Hao-Nan Wang

Affiliations

Soon will be listed here.

Abstract

Background: X-inactive specific transcript (XIST), it has been found, is abnormal expression in various neoplasms. This work aims to explore its potential molecular mechanisms and prognostic roles in types of malignancies.

Methods: This research comprehensively investigated XIST transcription across cancers from Oncomine, TIMER 2.0 and GEPIA2. Correlations of XIST expression with prognosis, miRNAs, interacting protens, immune infiltrates, checkpoint markers, mutations of tumor-associated genes and promoter methylation were also analyzed by public databases. In addition, 98 BRCA samples were collected to investigate XIST expression and evaluate its clinicopathological value.

Results: In public databases, compared to normal tissues, XIST was lower in BRCA, CESC, COAD and so on, but increased in KIRC and PRAD. Databases also showed that XIST was a good indicator of prognosis in BRCA, COAD and so on, but a bad one in KIRC, KIRP and so on. From starBase, we found 29 proteins interacting with XIST, and identified 4 miRNAs which might be sponged by XIST in cancers. Furthermore, XIST was linked with immune infiltration, especially T cell CD4+, and was related to over 20 immune checkpoint markers. Moreover, several tumor-associated gene mutations and promoter methylation were negatively related to its expression. In addition, IHC showed that XIST in BRCA was obviously lower in comparison of normal tissues and was negatively related to lymph node invasion and TNM stage.

Conclusion: In summary, abnormal expression of XIST influenced prognosis, miRNAs and immune infiltration across cancers, especially BRCA.

Citing Articles

Bridging gap in treatment of polycystic ovarian syndrome through drug repurposing: what we achieved and where we are?.

Kumbhar P, Chavan R, Darekar S, Kolekar K, Sequeira A, Vishwas S Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39520555 DOI: 10.1007/s00210-024-03578-7.

Exploring potential roles of long non-coding RNAs in cancer immunotherapy: a comprehensive review.

Arshi A, Mahmoudi E, Raeisi F, Dehghan Tezerjani M, Bahramian E, Ahmed Y Front Immunol. 2024; 15:1446937.

PMID: 39257589 PMC: 11384988. DOI: 10.3389/fimmu.2024.1446937.

Long noncoding RNA TMPO-AS1 upregulates BCAT1 expression to promote cell proliferation in nasopharyngeal carcinoma via microRNA let-7c-5p.

Wang H, Zhou F, Wan J, Yu H, Wang J Genes Environ. 2024; 46(1):14.

PMID: 38937856 PMC: 11210057. DOI: 10.1186/s41021-024-00308-6.

Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications.

Xiao T, Lee J, Gauntner T, Velegraki M, Lathia J, Li Z Nat Rev Cancer. 2024; 24(5):338-355.

PMID: 38589557 DOI: 10.1038/s41568-024-00680-z.

Discovering therapeutic possibilities for polycystic ovary syndrome by targeting XIST and its associated ceRNA network through the analysis of transcriptome data.

Berenji E, Motlagh A, Fathi M, Esmaeili M, Izadi T, Rezvanian P Sci Rep. 2024; 14(1):6180.

PMID: 38486041 PMC: 10940664. DOI: 10.1038/s41598-024-56524-1.

References

Zhang M, Sun W, Wu H, Liu Z, Wang P . Knockdown of microRNA-103a-3p inhibits the malignancy of thyroid cancer cells through Hippo signaling pathway by upregulating LATS1. Neoplasma. 2020; 67(6):1266-1278. DOI: 10.4149/neo_2020_191224N1331. View

Mu L, Ding K, Tu R, Yang W . Identification of 4 immune cells and a 5-lncRNA risk signature with prognosis for early-stage lung adenocarcinoma. J Transl Med. 2021; 19(1):127. PMC: 8004399. DOI: 10.1186/s12967-021-02800-x. View

Dreos R, Ambrosini G, Groux R, Cavin Perier R, Bucher P . The eukaryotic promoter database in its 30th year: focus on non-vertebrate organisms. Nucleic Acids Res. 2016; 45(D1):D51-D55. PMC: 5210552. DOI: 10.1093/nar/gkw1069. View

Bennett M, Cleaves K, Hewezi T . Expression Patterns of DNA Methylation and Demethylation Genes during Plant Development and in Response to Phytohormones. Int J Mol Sci. 2021; 22(18). PMC: 8470644. DOI: 10.3390/ijms22189681. View

Ma S, Wang Y, Li Y, Li X, Yang J, Sheng Y . LncRNA XIST promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by downregulating miR-27b-3p. J Biol Regul Homeost Agents. 2020; 34(6):1993-2001. DOI: 10.23812/20-222-A. View

Bai Y, Lin H, Chen J, Wu Y, Yu S . Identification of Prognostic Glycolysis-Related lncRNA Signature in Tumor Immune Microenvironment of Hepatocellular Carcinoma. Front Mol Biosci. 2021; 8:645084. PMC: 8100457. DOI: 10.3389/fmolb.2021.645084. View

Su G, Yan Z, Deng M . Sevoflurane Inhibits Proliferation, Invasion, but Enhances Apoptosis of Lung Cancer Cells by Wnt/β-catenin Signaling via Regulating lncRNA PCAT6/miR-326 Axis. Open Life Sci. 2021; 15:159-172. PMC: 8114787. DOI: 10.1515/biol-2020-0017. View

Saraf R, Agah S, Datta A, Jiang X . Drug target ranking for glioblastoma multiforme. BMC Biomed Eng. 2021; 3(1):7. PMC: 8074458. DOI: 10.1186/s42490-021-00052-w. View

Xiong Z, Li M, Yang F, Ma Y, Sang J, Li R . EWAS Data Hub: a resource of DNA methylation array data and metadata. Nucleic Acids Res. 2019; 48(D1):D890-D895. PMC: 6943079. DOI: 10.1093/nar/gkz840. View

10.

Machado C, da Silva E, Dias Nogueira B, de Moraes Filho M, Montenegro R, de Moraes M . PARP1 Is Overexpressed in Hematological Malignant Cell Lines: A Framework for Experimental Oncology. Anticancer Res. 2021; 41(5):2397-2402. DOI: 10.21873/anticanres.15014. View

11.

Pathania A, Challagundla K . Exosomal Long Non-coding RNAs: Emerging Players in the Tumor Microenvironment. Mol Ther Nucleic Acids. 2021; 23:1371-1383. PMC: 7940039. DOI: 10.1016/j.omtn.2020.09.039. View

12.

Wang Y, Chen S, Li W, Jiang R, Wang Y . Associating divergent lncRNAs with target genes by integrating genome sequence, gene expression and chromatin accessibility data. NAR Genom Bioinform. 2021; 2(2):lqaa019. PMC: 7671357. DOI: 10.1093/nargab/lqaa019. View

13.

Yan W, Wang Y, Chen Y, Guo Y, Li Q, Wei X . Exosomal miR-130b-3p Promotes Progression and Tubular Formation Through Targeting PTEN in Oral Squamous Cell Carcinoma. Front Cell Dev Biol. 2021; 9:616306. PMC: 8019696. DOI: 10.3389/fcell.2021.616306. View

14.

Xu J, Li H, Lv Y, Zhang C, Chen Y, Yu D . Silencing XIST mitigated lipopolysaccharide (LPS)-induced inflammatory injury in human lung fibroblast WI-38 cells through modulating miR-30b-5p/CCL16 axis and TLR4/NF-κB signaling pathway. Open Life Sci. 2021; 16(1):108-127. PMC: 7988359. DOI: 10.1515/biol-2021-0005. View

15.

Yu B, Qi Y, Li R, Shi Q, Satpathy A, Chang H . B cell-specific XIST complex enforces X-inactivation and restrains atypical B cells. Cell. 2021; 184(7):1790-1803.e17. PMC: 9196326. DOI: 10.1016/j.cell.2021.02.015. View

16.

Zuo K, Zhao Y, Zheng Y, Chen D, Liu X, Du S . Long non-coding RNA XIST promotes malignant behavior of epithelial ovarian cancer. Onco Targets Ther. 2019; 12:7261-7267. PMC: 6733346. DOI: 10.2147/OTT.S204369. View

17.

Wang B, Liu X, Meng X . miR-96-5p enhances cell proliferation and invasion via targeted regulation of ZDHHC5 in gastric cancer. Biosci Rep. 2020; 40(4). PMC: 7160376. DOI: 10.1042/BSR20191845. View

18.

Liu B, Luo C, Lin H, Ji X, Zhang E, Li X . Long Noncoding RNA Acts as a ceRNA of miR-362-5p to Suppress Breast Cancer Progression. Cancer Biother Radiopharm. 2020; 36(6):456-466. DOI: 10.1089/cbr.2019.3481. View

19.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

20.

Li Y, Wang L, Rivera-Serrano E, Chen X, Lemon S . TNRC6 proteins modulate hepatitis C virus replication by spatially regulating the binding of miR-122/Ago2 complexes to viral RNA. Nucleic Acids Res. 2019; 47(12):6411-6424. PMC: 6614814. DOI: 10.1093/nar/gkz278. View